Skip to main content

Ferriprox Side Effects

Generic name: deferiprone

Medically reviewed by Last updated on Jul 6, 2023.

Note: This document contains side effect information about deferiprone. Some dosage forms listed on this page may not apply to the brand name Ferriprox.

Applies to deferiprone: oral solution, oral tablet.


Oral route (Tablet; Solution)

Agranulocytosis and NeutropeniaDeferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor regularly while on therapy.Interrupt deferiprone therapy if neutropenia develops.Interrupt deferiprone if infection develops, and monitor the ANC more frequently.Advise patients taking deferiprone to report immediately any symptoms indicative of infection

Serious side effects of Ferriprox

Along with its needed effects, deferiprone (the active ingredient contained in Ferriprox) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking deferiprone:

More common

Less common

Incidence not known

Other side effects of Ferriprox

Some side effects of deferiprone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to deferiprone: oral liquid, oral tablet.


The most common adverse events were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia, and neutropenia.[Ref]


Very common (10% or more): Nausea (12.6%), abdominal pain/discomfort (10.4%), vomiting

Common (1% to 10%): Diarrhea, dyspepsia, abdominal discomfort, abdominal pain, abdominal pain upper

Uncommon (0.1% to 1%): Abdominal distension, abdominal pain lower, aphthous stomatitis, constipation, epigastric discomfort, eructation, gastritis, reflux esophagitis, stomach discomfort, gastroenteritis, gastroenteritis viral

Postmarketing reports: Enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement, cecitis, dysphagia[Ref]

Gastrointestinal effects are more frequent at the beginning of therapy, and in most patients resolve within a few weeks without the discontinuation of treatment.[Ref]


Very common (10% or more): Chromaturia (14.6%)

Uncommon (0.1% to 1%): Pollakiuria, amenorrhea, menstruation irregular

Postmarketing reports: Glycosuria, hypospadias, congenital anomaly, non-acute porphyria, urinary tract infection, urine color abnormal, intra-uterine death, balanitis[Ref]


Very common (10% or more): Arthralgia

Common (1% to 10%): Back pain, pain in extremity, arthropathy, joint swelling

Uncommon (0.1% to 1%): Epicondylitis, arthritis, bone pain, joint crepitation, joint effusion, joint range of motion decreased, joint stiffness, metatarsalgia, muscle spasms, muscular weakness, musculoskeletal chest pain, musculoskeletal pain, myalgia, polyarthritis, synovial cyst

Postmarketing reports: Myositis, chondropathy, trismus[Ref]


Common (1% to 10%): Neutrophil count decreased, neutropenia, agranulocytosis, white blood cell count decreased

Uncommon (0.1% to 1%): Blood disorder, hypersplenism, leukopenia, thrombocytopenia, platelet count decreased, platelet count increased

Postmarketing reports: Thrombocytosis, pancytopenia, febrile neutropenia, thrombocythemia, granulocytopenia, hemoglobin decrease, neutropenic sepsis[Ref]


Common (1% to 10%): Alanine aminotransferase increased, aspartate aminotransferase increased, increased liver enzymes

Uncommon (0.1% to 1%): Hepatic pain, hepatitis, hepatomegaly, jaundice, liver tenderness, cytomegalovirus hepatitis, blood bilirubin increased, hepatic enzyme increased

Postmarketing reports: Hepatic function abnormal, infectious hepatitis[Ref]


Common (1% to 10%): Fatigue, peripheral edema

Uncommon (0.1% to 1%): Deafness, ear pain, tinnitus, vertigo, asthenia, chest pain, discomfort, fatigue, influenza like illness, malaise, pyrexia, thirst, diabetic foot infection, sepsis, Yersinia infection, transfusion reaction, blood creatinine increased, blood phosphorus increased, blood zinc decreased, gamma-glutamyl transferase increased

Frequency not reported: Progression of fibrosis

Postmarketing reports: Chills, multi-organ failure, pharyngitis, pneumonia, sepsis, blood creatinine phosphokinase increased, difficulty in walking, hyperpyrexia, anti-HBs antibody positive, blood arsenic increased[Ref]


Common (1% to 10%): Increased appetite, weight increased, decreased appetite, anorexia

Uncommon (0.1% to 1%): Weight decreased, fluid retention

Postmarketing reports: Metabolic acidosis, dehydration, metabolic disorder[Ref]


Uncommon (0.1% to 1%): Influenza, nasopharyngitis, upper respiratory tract infection, asthma, dry throat, oropharyngeal pain

Postmarketing reports: Acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism, respiratory acidosis, dyspnea, lung disorder, oropharyngolaryngeal pain, pharyngeal erythema, tonsillitis, parapharyngeal abscess[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Dizziness, hypogeusia, migraine, somnolence

Frequency not reported: Psychomotor slowdown, hand movements, axial hypotonia

Postmarketing reports: Cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, dystonia, febrile convulsion, coordination abnormal, hypotonia, nystagmus, depressed level of consciousness, balance disorder, enteroviral encephalitis[Ref]


Uncommon (0.1% to 1%): Hypersensitivity

Postmarketing reports: Anaphylactic shock[Ref]


Uncommon (0.1% to 1%): Arrhythmia, Torsades de Pointes, electrocardiogram T wave inversion

Postmarketing reports: Atrial fibrillation, cardiac failure, hypotension, hypertension, cardiac disorder, congestive cardiac failure, sinus tachycardia[Ref]


Uncommon (0.1% to 1%): Alopecia, hyperhidrosis, pruritus, rash, rash generalized, rash pruritic, skin hypopigmentation, urticaria, xeroderma

Frequency not reported: Henoch-Schönlein purpura, urticaria, periorbital edema with skin rash

Postmarketing reports: Cryptococcal cutaneous infection, rash pustular, subcutaneous abscess, hyperhidrosis, photosensitivity reaction, rash erythematous, rash maculopapular, face edema, furuncle, subcutaneous abscess[Ref]


Postmarketing reports: Hemoglobinuria, renal failure, glycosuria, chromaturia[Ref]


Postmarketing reports: Blood corticotrophin decreased, blood cortisol decreased[Ref]


Frequency not reported: Lateral nystagmus

Postmarketing reports: Diplopia, papilledema, retinal toxicity, eye movement disorder, periorbital edema, retinal toxicity, visual impairment[Ref]


Postmarketing reports: Hepatic neoplasm malignant[Ref]


Postmarketing reports: Bruxism, depression, obsessive-compulsive disorder[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Ferriprox (deferiprone). ApoPharma USA Inc. 2011.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.